Preterm Infants and Surfactant: Should You Give it to Every Baby?
<>
For preterm infants born before 37 weeks with respiratory distress syndrome, administering surfactant preventively alongside continuous positive airway pressure may slightly increase mortality risk compared to selective administration after symptoms develop, according to updated Cochrane review evidence current to January 31, 2025.
Key Clinical Takeaways:
- Preterm infants receiving continuous positive airway pressure at birth face a slightly higher mortality risk when given prophylactic surfactant compared to targeted, selective dosing.
- Infants not stabilized with continuous positive airway pressure show a reduced mortality risk when treated with prophylactic surfactant shortly after birth.
- Current clinical evaluation favors early airway stabilization with continuous positive airway pressure for all at-risk preterm infants, reserving surfactant therapy exclusively for those who present with active symptoms of respiratory distress syndrome.
Fresh Evidence From 10 Clinical Studies
The updated analysis examines 10 clinical studies encompassing 3,151 preterm infants, refreshing the previous 2012 Cochrane review standards. Preterm birth—defined as delivery prior to 37 weeks of gestation—frequently interrupts the natural production of pulmonary surfactant, a complex mixture of endogenous lipids and proteins that reduces surface tension within the alveolar air sacs. Without sufficient surfactant, neonatal alveoli collapse, precipitating respiratory distress syndrome and severe hypoxemia. Decades-old clinical trials previously established prophylactic surfactant administration via endotracheal intubation immediately following birth as standard practice to prevent these complications. Modern neonatal intensive care units, however, increasingly rely on non-invasive respiratory support strategies.
Divergent Outcomes With Airway Pressure
The comparative data reveal divergent outcomes depending on whether infants receive continuous positive airway pressure. When evaluating studies where infants were treated with continuous positive airway pressure, prophylactic surfactant administration probably results in little to no difference in chronic lung disease risk—defined as the need for long-term oxygen supplementation—while likely increasing neonatal mortality compared with selective surfactant use. Conversely, in trials where infants did not receive continuous positive airway pressure, prophylactic surfactant delivery reduced mortality risk and slightly decreased the incidence of pneumothorax, though evidence regarding chronic lung disease remains highly uncertain across these older cohorts. Across all 1,874 infants evaluated in five studies tracking chronic lung disease outcomes, prophylactic and selective strategies showed comparable long-term pulmonary profiles.
Protocol Management and Compliance
Navigating these complex neonatal protocols requires strict adherence to evidence-based guidelines and coordinated clinical oversight.
Addressing Remaining Evidentiary Gaps
Future investigations must address remaining evidentiary gaps, including the specific physiological responses of extremely preterm infants born before 28 weeks gestation, maternal prenatal corticosteroid exposure, and varying delivery devices. Translating these evolving insights into bedside practice remains vital for minimizing invasive interventions and improving survival rates in vulnerable neonatal populations.